UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Targeting Peripheral CB1 Receptors Reduces Ethanol Intake via a Gut-Brain Axis

Cell metabolism, 2019-06, Vol.29 (6), p.1320-1333.e8

2019

Volltextzugriff (PDF)

SUN-LB082 Sexual Dimorphism of Phosphoethanolamine in HPA-Axis Response to LXR Agonist 25-Hydroxycholesterol: Neuroendocrine Implications for Major Depressive Disorder

Journal of the Endocrine Society, 2019-04, Vol.3 (Supplement_1)

2019

Volltextzugriff (PDF)

SUN-LB081 LXR Agonist 25-Hydroxycholesterol Modulates Plasma, Adrenal, and Hypothalamic Phosphoethanolamine Levels: Neuroendocrine Implications for HPA-Axis in Major Depressive Disorder

Journal of the Endocrine Society, 2019-04, Vol.3 (Supplement_1)

2019

Volltextzugriff (PDF)

Plasma metabolome analysis of patients with major depressive disorder

Psychiatry and clinical neurosciences, 2018-05, Vol.72 (5), p.349-361

2018

Volltextzugriff (PDF)

Biologically active, high levels of interleukin-22 inhibit hepatic gluconeogenesis but do not affect obesity and its metabolic consequences

Cell & bioscience, 2015-05, Vol.5 (1), p.25-25, Article 25

2015

Volltextzugriff (PDF)

Dietary Linoleic Acid Elevates Endogenous Endocannabinoids (2‐AG and Anandamide) and Induces Obesity

The FASEB journal, 2013-04, Vol.27 (S1)

2013

Volltextzugriff (PDF)

NOVEL INHIBITOR OF FATTY ACID AMIDE HYDROLASE NORMALIZES CARDIOVASCULAR FUNCTION IN HYPERTENSION WITHOUT ADVERSE METABOLIC EFFECTS

Chemistry & biology, 2010-11, Vol.17 (11), p.1256-1266

2010

Volltextzugriff (PDF)

Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

The Journal of clinical investigation, 2010-10, Vol.120 (10), p.3735-3735

2010

Volltextzugriff (PDF)

Transcriptional Regulation of Cannabinoid Receptor-1 Expression in the Liver by Retinoic Acid Acting via Retinoic Acid Receptor-g

The Journal of biological chemistry, 2010-06, Vol.285 (25), p.19002-19011

2010

Volltextzugriff (PDF)

Opinion: Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain?

Trends in pharmacological sciences (Regular ed.), 2009-01, Vol.30 (1), p.1-7

2009

Volltextzugriff (PDF)

Should peripheral CB 1 cannabinoid receptors be selectively targeted for therapeutic gain?

Trends in pharmacological sciences (Regular ed.), 2009, Vol.30 (1), p.1-7

2009

Volltextzugriff (PDF)

The Role of Endocannabinoids and Their Receptors in the Control of Hepatic Functions

The Liver, 2009, p.1091-1103

2009

Volltextzugriff (PDF)

PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid ω-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease

PPAR Research, 2009-01, Vol.2009, p.952734-952734

2009

Volltextzugriff (PDF)

PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid -Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease

PPAR research, 2009, Vol.2009, p.1-20

2009

Volltextzugriff (PDF)

Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain?

Trends in pharmacological sciences (Regular ed.), 2009-01, Vol.30 (1), p.1-7

2009

Volltextzugriff (PDF)

Hepatic [CB.sub.1] receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice

The Journal of clinical investigation, 2008-09, Vol.118 (9), p.3160

2008

Volltextzugriff (PDF)

Hepatic CB^sub 1^ receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice

The Journal of clinical investigation, 2008-09, Vol.118 (9), p.3160

2008

Volltextzugriff (PDF)

Cell type-dependent pro- and anti-inflammatory role of STAT3 in alcoholic liver injury

Gastroenterology (New York, N.Y. 1943), 2008-01, Vol.134 (4), p.1148-1158

2008

Volltextzugriff (PDF)

Endocannabinoids and Liver Disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis

American journal of physiology: Gastrointestinal and liver physiology, 2008, Vol.57 (5)

2008

Volltextzugriff (PDF)

Paracrine Activation of Hepatic CB 1 Receptors by Stellate Cell-Derived Endocannabinoids Mediates Alcoholic Fatty Liver

Cell metabolism, 2008, Vol.7 (3), p.227-235

2008

Volltextzugriff (PDF)

Pivotal Advance: Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis

Journal of leukocyte biology, 2007-12, Vol.82 (6), p.1382-1389

2007

Volltextzugriff (PDF)

Endocannabinoid system in cancer cachexia

Current opinion in clinical nutrition and metabolic care, 2007-07, Vol.10 (4), p.443-448

Osei-Hyiaman, Douglas

2007

Volltextzugriff (PDF)

The role of the endocannabinoid system in liver ischemia reperfusion injury

The FASEB journal, 2007, Vol.21 (6), p.A807-A807

2007

Volltextzugriff (PDF)

Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase

American journal of physiology. Heart and circulatory physiology, 2005-08, Vol.58 (2), p.H533-H541

2005

Volltextzugriff (PDF)

Endocannabinoid activation at hepatic CB sub(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

The Journal of clinical investigation, 2005-05, Vol.115 (5), p.1298-1305

2005

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Aktive Filter

ThemaAnimals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(32)
Buchkapitel
(1)

Sprache

Englisch
(33)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Targeting Peripheral CB1 Receptors Reduces Ethanol Intake via a Gut-Brain Axis

SUN-LB082 Sexual Dimorphism of Phosphoethanolamine in HPA-Axis Response to LXR Agonist 25-Hydroxycholesterol: Neuroendocrine Implications for Major Depressive Disorder

SUN-LB081 LXR Agonist 25-Hydroxycholesterol Modulates Plasma, Adrenal, and Hypothalamic Phosphoethanolamine Levels: Neuroendocrine Implications for HPA-Axis in Major Depressive Disorder

Plasma metabolome analysis of patients with major depressive disorder

Biologically active, high levels of interleukin-22 inhibit hepatic gluconeogenesis but do not affect obesity and its metabolic consequences

Dietary Linoleic Acid Elevates Endogenous Endocannabinoids (2‐AG and Anandamide) and Induces Obesity

NOVEL INHIBITOR OF FATTY ACID AMIDE HYDROLASE NORMALIZES CARDIOVASCULAR FUNCTION IN HYPERTENSION WITHOUT ADVERSE METABOLIC EFFECTS

Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

Transcriptional Regulation of Cannabinoid Receptor-1 Expression in the Liver by Retinoic Acid Acting via Retinoic Acid Receptor-g

Opinion: Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain?

Should peripheral CB 1 cannabinoid receptors be selectively targeted for therapeutic gain?

The Role of Endocannabinoids and Their Receptors in the Control of Hepatic Functions

PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid ω-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease

PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid -Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease

Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain?

Hepatic [CB.sub.1] receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice

Hepatic CB^sub 1^ receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice

Cell type-dependent pro- and anti-inflammatory role of STAT3 in alcoholic liver injury

Endocannabinoids and Liver Disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis

Paracrine Activation of Hepatic CB 1 Receptors by Stellate Cell-Derived Endocannabinoids Mediates Alcoholic Fatty Liver

Pivotal Advance: Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis

Endocannabinoid system in cancer cachexia

The role of the endocannabinoid system in liver ischemia reperfusion injury

Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase

Endocannabinoid activation at hepatic CB sub(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

Aktive Filter

Suchergebnisse filtern